Genmab shares fall after cancer drug trial failed to meet endpoint

Shares in Denmark's Genmab GMAB.CO fall around 6% after the drugmaker and its U.S. partner AbbVie ABBV.N said their phase 3 trial for a blood cancer drug failed to meet endpoint

Epcoritamab failed to improve the survival rate in patients in the late-stage study, the companies say

"We would view a small correction in the shares as a buying opportunity into Genmab as one of our top picks," Van Lanschot Kempen says

J.P.Morgan says it is disappointing to see the failure of the EPCORE DLBCL-1 trial

It expects the focus to remain on the more significant 1L DLBCL trial readout in mid-2026 where Genmab seems more confident on positive results

U.S.-listed shares of Genmab lost more than 7% in afternoon trade on Friday

If losses hold, Genmab shares will see their worst day since April